Private company

Poseida Therapeutics, Inc.

In its 2024 annual report the company says: “We are a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies.”4 It is headquartered in San Diego, United States.2

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address9390 Towne Centre Drive, Suite 200, San Diego, Ca 921213
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300USKSDMNGMN8V042
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 56590212

See how the biggest companies compare on our leaderboards

We are a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-200.2%Operating margin5
-190.8%Net margin5
-50.4%Revenue growth, 20235
-119.0%Return on equity5
0.56×Debt to equity5
-$95.2MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development95¢$156.8M
  • Interest5¢$8.7M
  • Income tax0¢$107.0K

Out of $64.7M in revenue.5 The company lost money this year.

Financial statements

Revenue65$64.7M in 2023+107% since 2021
0$50.0M$100.0M$150.0M2021: $31.2M$31.2M20212022: $130.5M$130.5M2022+318%2023: $64.7M$64.7M2023−50%
Operating income7865-$129.5M in 2023+51% since 2019
-$150.0M-$100.0M-$50.0M02019: -$85.5M-$85.5M20192020: -$126.5M-$126.5M2020+48%2021: -$141.4M-$141.4M2021+12%2022: -$59.9M-$59.9M2022−58%2023: -$129.5M-$129.5M2023+116%
Net income7865-$123.4M in 2023+43% since 2019
-$150.0M-$100.0M-$50.0M02019: -$86.5M-$86.5M20192020: -$129.8M-$129.8M2020+50%2021: -$125.0M-$125.0M2021−4%2022: -$64.0M-$64.0M2022−49%2023: -$123.4M-$123.4M2023+93%
Fiscal year201820192020202120222023
Revenue$31.2M6$130.5M5$64.7M5
Research and development$60.4M7$103.5M8$136.7M6$152.9M5$156.8M5
Operating expenses$172.6M6$190.4M5$194.2M5
Operating income-$85.5M7-$126.5M8-$141.4M6-$59.9M5-$129.5M5
Interest$3.6M7$3.5M8$3.4M6$6.4M5$8.7M5
Income before tax-$125.0M6-$63.5M5-$123.3M5
Income tax$07$08$08$544.0K5$107.0K5
Net income-$86.5M7-$129.8M8-$125.0M6-$64.0M5-$123.4M5
Earnings per share-$2.016-$0.895-$1.375
Earnings per share (diluted)-$2.016-$0.895-$1.375
Shares (weighted, basic)62.2M shares672.0M shares590.2M shares5
Shares (weighted, diluted)62.2M shares672.0M shares590.2M shares5

Compare Poseida Therapeutics, Inc. with another company

Corporate structure

Poseida Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Poseida Therapeutics, Inc.

  • FMR LLC Filed SCHEDULE 13G/A on Poseida Therapeutics, Inc., latest Feb 7, 2025 (5 filings since Feb 9, 2022)
  • Malin Life Sciences Holdings Ltd Filed SCHEDULE 13G/A on Poseida Therapeutics, Inc., latest Jan 15, 2025
  • Pentwater Capital Management LP Filed SCHEDULE 13D/A on Poseida Therapeutics, Inc., latest Jan 13, 2025 (3 filings since Apr 25, 2022)
  • BlackRock Filed SC 13G on Poseida Therapeutics, Inc., latest Nov 8, 2024 (2 filings since Oct 22, 2024)
  • Novartis Filed SC 13G/A on Poseida Therapeutics, Inc., latest May 8, 2024
  • Astellas US LLC Filed SC 13D on Poseida Therapeutics, Inc., latest Aug 14, 2023
  • Poseida Therapeutics, Inc. San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Poseida Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$37.9M5 Dec 31, 2023$35.1M5 Dec 31, 2022+8.0%
Accumulated depreciation$18.8M5 Dec 31, 2023$13.5M5 Dec 31, 2022+39.6%
Property and equipment, net$19.1M5 Dec 31, 2023$21.6M5 Dec 31, 2022−11.7%
Operating-lease assets (leased space)$21.7M5 Dec 31, 2023$25.1M5 Dec 31, 2022−13.4%

Real estate and locations

ItemLatestA year beforeChange
Area of land110,000 sq ft5 Dec 31, 2023110,000 sq ft6 Dec 31, 20220%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$44.5M5 Dec 31, 2023$81.4M5 Dec 31, 2022−45.4%
Marketable securities, current$167.7M5 Dec 31, 2023$201.1M5 Dec 31, 2022−16.6%
Marketable securities, non-current$06 Dec 31, 2022$06 Dec 31, 2021
Debt securities available for sale$205.3M5 Dec 31, 2023$264.2M5 Dec 31, 2022−22.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$4.2M5 Dec 31, 2023$4.2M5 Dec 31, 20220%
Intangible assets, net (excluding goodwill)$1.3M5 Dec 31, 2023$1.3M5 Dec 31, 20220%
Indefinite-lived intangibles (excluding goodwill)$1.3M6 Dec 31, 2022$1.3M6 Dec 31, 20210%

Leadership

Who has led Poseida Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Eric Ostertag2020–2021
  2. Mark J. Gergen2022–2025
  3. Kristin Yarema2024–2025

Chair

  1. Eric Ostertag2022
  2. Mark J. Gergen2024–2025

President

  1. Mark J. Gergen2020–2025
  2. Brent Warner2022–2024
  3. Kristin Yarema2023–2025

Chief financial officer

  1. Johanna Mylet2021–2025

Chief operating officer

  1. Kerry D. Ingalls2020–2022
2025
Board members and other officers (14)

Timeline

  1. Jan 8, 20258-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer32
  2. Nov 26, 20248-K Entered a material agreement; Other events33
  3. Nov 14, 20248-K Regulation FD disclosure34
  4. Nov 7, 20248-K Results of operations35
  5. Sep 30, 20248-K Other events36
  6. Aug 5, 20248-K Results of operations37
  7. Jun 18, 20248-K Shareholder vote38
  8. May 14, 20248-K Results of operations39
  9. May 1, 20248-K Entered a material agreement; Regulation FD disclosure40
  10. Apr 17, 20248-K Regulation FD disclosure41
  11. Apr 8, 20248-K Regulation FD disclosure42
  12. Mar 7, 20248-K Results of operations; Executive or director change43
  13. Jan 4, 2024New chief executive Kristin Yarema becomes CEO11
  14. Feb 1, 2022New chief executive Mark J. Gergen becomes CEO12
  15. Jul 9, 2020New chief executive Eric Ostertag becomes CEO13

Calendar

When it reported results

  1. Nov 7, 2024Reported quarterly or annual results35
  2. Aug 5, 2024Reported quarterly or annual results37
  3. May 14, 2024Reported quarterly or annual results39
  4. Mar 7, 2024Reported quarterly or annual results43
  5. Nov 9, 2023Reported quarterly or annual results44
  6. Aug 8, 2023Reported quarterly or annual results45
  7. May 9, 2023Reported quarterly or annual results46
  8. Mar 9, 2023Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

198 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 47 major events, 77 insider forms, 13 large holders, 1 private raises, 47 other. The latest 20:

  1. Feb 7, 2025SCHEDULE 13G/A EDGAR
  2. Feb 7, 2025SCHEDULE 13G/A EDGAR
  3. Jan 21, 202515-12G EDGAR
  4. Jan 15, 2025SCHEDULE 13G/A EDGAR
  5. Jan 13, 2025SCHEDULE 13D/A EDGAR
  6. Jan 10, 2025EFFECT EDGAR
  7. Jan 10, 2025EFFECT EDGAR
  8. Jan 10, 20254 OWNERSHIP DOCUMENT EDGAR
  9. Jan 8, 20254 EDGAR
  10. Jan 8, 20254 EDGAR
  11. Jan 8, 20254 EDGAR
  12. Jan 8, 20254 EDGAR
  13. Jan 8, 20254 EDGAR
  14. Jan 8, 20254 EDGAR
  15. Jan 8, 20254 EDGAR
  16. Jan 8, 20254 EDGAR
  17. Jan 8, 20254 EDGAR
  18. Jan 8, 20254 EDGAR
  19. Jan 8, 20254 EDGAR
  20. Jan 8, 2025S-8 POS EDGAR

The 198 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

21 open-market trades by officers, directors and large owners since October 2021: 16 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 10, 2024Gergen Mark JPresident and CEOSale30,000$9.46$283.8KForm 4
Nov 26, 2024Gergen Mark JPresident and CEOSale30,000$9.27$278.1KForm 4
Aug 8, 2022Ostertag EricDirectorBuy142,857$3.50$500.0KForm 4
Aug 8, 2022Malin Life Sciences Holdings Ltd10% ownerBuy2,150,000$3.50$7.5MForm 4
Aug 3, 2022Ostertag EricDirectorSale160,696$3.69$593.0KForm 4
Mar 16, 2022Ingalls Kerry D.Chief Operating OfficerBuy3,000$3.98$11.9KForm 4
Dec 6, 2021Malin Life Sciences Holdings Ltd10% ownerBuy1,828$6.90$12.6KForm 4
Dec 2, 2021Malin Life Sciences Holdings Ltd10% ownerBuy4,296$6.88$29.6KForm 4
Dec 1, 2021Malin Life Sciences Holdings Ltd10% ownerBuy18,365$6.85$125.8KForm 4
Nov 30, 2021Malin Life Sciences Holdings Ltd10% ownerBuy28,592$6.85$195.9KForm 4
Nov 29, 2021Malin Life Sciences Holdings Ltd10% ownerBuy11,057$6.89$76.2KForm 4
Nov 26, 2021Malin Life Sciences Holdings Ltd10% ownerBuy27,251$6.81$185.6KForm 4
Nov 24, 2021Malin Life Sciences Holdings Ltd10% ownerBuy1,054$6.89$7.3KForm 4
Nov 23, 2021Malin Life Sciences Holdings Ltd10% ownerBuy14,625$6.77$99.0KForm 4
Nov 19, 2021Malin Life Sciences Holdings Ltd10% ownerBuy11,104$7.44$82.6KForm 4
Nov 18, 2021Malin Life Sciences Holdings Ltd10% ownerBuy71,312$7.18$512.0KForm 4
Nov 17, 2021Ingalls Kerry D.Chief Operating OfficerBuy2,000$7.00$14.0KForm 4
Nov 17, 2021Malin Life Sciences Holdings Ltd10% ownerBuy280,384$7.21$2.0MForm 4
Nov 16, 2021Malin Life Sciences Holdings Ltd10% ownerBuy27,680$7.17$198.5KForm 4
Nov 8, 2021Ostertag EricDirectorSale18,924$7.09$134.2KForm 4

All 21 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 7, 2023Raised $25 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How Poseida Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPoseida Therapeutics, Inc.1
  • CIK0001661460
  • Employer ID (EIN)47-28465481
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address9390 Towne Centre Drive, Suite 200, San Diego, CA 921211
  • Phone858-779-31001
  • Shares outstanding97,465,024 as of Nov 1, 202410
  • Public float$122.8M as of Jun 30, 20235
  • On EDGAR sinceDec 24, 20151
  • Filings335 in all: 4 (121), 8-K (63), 3 (20), 10-Q (14), UPLOAD (10), CORRESP (9), EFFECT (6), SC 13G (6)1
    All 44 form types

    SC 13G/A (6), D (5), DEFA14A (5), S-8 (5), S-8 POS (5), 10-K (4), DEF 14A (4), SC 14D9/A (4), SC TO-T/A (4), SCHEDULE 13G/A (4), S-1/A (3), S-3 (3), 424B5 (2), ARS (2), DRS (2), DRS/A (2), POS AM (2), S-1 (2), SC 13D (2), SC 13D/A (2), SC TO-C (2), SC14D9C (2), 144 (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 5 (1), 8-A12B (1), CERT (1), DRSLTR (1), RW (1), SC 14D9 (1), SC TO-T (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 7, 2024
    Quarterly report (10-Q) Nov 7, 2024
    Proxy statement (DEF 14A) Apr 25, 2024
    Latest 8-K (8-K) Jan 8, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53